



ADVANCES IN
CARDIAC
ELECTROPHYSIOLOGY



PVI with multielectrode RF catheter: long term outcome of the PVAC GOLD catheter

*Dr Giovanni Rovaris
Chief of Electrophysiology
San Gerardo, Monza (MB)*



Azienda Ospedaliera


San Gerardo

di rilievo nazionale ad alta specializzazione

PHASED RF TECHNOLOGY

ContactIQ

effective contact = f (power + temperature)



Next Generation PVAC[®]




GENius Contact IQ®

- **ContactIQ®** provides precise management of power and temperature to simplify decision-making and ablation effectiveness assessment
- **Effective contact** displayed by target temperature and power $>3W$ - Green bars
- **Only effective contact** (heating time) per electrode **displayed**



New User Interface Enhances Decision Making

- *De Greef et al* have demonstrated that good power and good temperature produces effective lesions¹
- New ContactIQ user interface highlights electrodes with both good power and good temperature
- Users' impressions of the new user interface have been strong. According to a recent survey,



Green Bar
50 - 65°C +
Power ≥ 3W

Yellow Bar/Black
Box
50 - 65°C + Power
< 3W

Yellow Bar/
White Box
< 50°C



New User Interface Enhances Decision Making



Scenario 3: **INEFFECTIVE** Lesion Creation: Low/No Contact

- Yellow bars < 45 °C suggest tissue contact is minimal
- Max power delivery of 8 W suggests **Limited Tissue Contact**
- Gently **INCREASING** contact pressure may increase temperature to green range


GENius Contact IQ®



Temp. > 48°C + power > 3W = enhance long term outcome (LESION)



Effective contact = **green bar**




99% ppv for making lesion with **30 sds.** of effective contact

¹ De Greef Y et al. Impact of radiofrequency characteristics on acute pulmonary vein reconnection and clinical outcome following PVAC ablation. doi:10.1111/jce.12021


Contact Recognition & Outcome

Contact Recognition Improves Outcomes Combination of power and temperature is predictive of outcomes


PV Isolation after 1hr & Adenosine Challenge	% Low Power RF apps (>48°, <3W)
Reconnection	27% ± 13%
No Reconnection	13% ± 15%




Patient Outcome @ 12 months (n=80)	% Low Power RF apps (>48°, <3W)
AF recurrence	28% ± 18%
Free from AF	11% ± 11%




RF 'ON' – Electrode Delivers Current, Tissue Heats



**Duty-Cycled RF
Heats tissue when ON**



RF 'OFF' – Electrode Cooling Pulls Heat from Surface,
Tissue at Depth Holds and Conducts Heat




Duty-Cycled RF
Cools electrode when OFF

RF Power Delivery


Duty-Cycled vs. Conventional



Conventional RF



Duty-Cycled RF

Power delivery
independently controlled
for each electrode





Score 1: Smooth borderline to tissue without fluctuation in depth
 Score 4: Lack of continuity with gaps


- Myocardial tissue has a high thermal storage capacity requiring 3 times as much time to cool as the level of tissue energy input
 - Electrodes can be OFF without tissue losing enough heat to affect lesion size and shape
- Duty-Cycled Energy Creates Deeper, More Homogenous Lesions**

Adapted from Erdogan A et al. *Homogeneity and diameter of linear lesions induced with multipolar ablation catheters: In vitro and in vivo comparison of Pulsed vs continuous radiofrequency energy delivery.* JICE 4, 655-661 (2000)

PVAC GOLD

- Eliminate 1:10 electrode interaction
- Gold thermal conductivity (4x greater than platinum) allows more uniform heating and faster cooling than platinum providing precise temperature control across the electrode
- Improved uniformity of electrode contact force
- Over-the-wire design provides stability in all anatomies

Gold



9 Electrodes



3.75mm Spacing




20° Forward Tilt

Platinum



10 Electrodes






3mm Spacing



Perpendicular

Next Generation PVAC[®]



Comparison of Gold Versus Platinum Electrodes on Myocardial Lesion Size Using Radiofrequency Energy

WALTER N. SIMMONS, SEAN MACKEY, DING SHENG HE, and FRANK I. MARCUS

From the Cardiology Section, Department of Medicine, and the Department of Electrical and Computer Engineering, University of Arizona, College of Medicine, Tucson, Arizona

(PACE 1996; 19[Pt. I]:398-402)



Gold has 4 times greater thermal conductivity

Platinum

71 $\frac{W}{mK}$



x 4

Gold

318 $\frac{W}{mK}$

Temperature Control

Temperature differential across the electrode is less with gold than platinum in the in-vitro perfusion test set-up





Temperature Control

Thermocouple placement



- Placed at electrode-tissue interface to improve accuracy of temperature measurement
- Temperature control using precise tissue interface temperature eliminates possibility of steam pops

Thermocouple at
electrode/tissue
interface



Better Lesions Under Low-Flow Conditions

PVAC GOLD produced deeper lesions versus PVAC under low flow conditions due to the improved cooling ability of gold¹




- **Coagulum:** no evidence was observed on catheter or thigh muscle.

PVAC GOLD is More Efficient than PVAC


Procedures were performed with 30% fewer RF applications with PVAC GOLD

	ERACE	PRECISION GOLD
Procedure Time	100 ± 35 min	92 ± 25 min
LA Dwell Time	64 ± 27 min	59 ± 17 min
Fluoroscopy Time	-	16 ± 6 min
Average Effective Contact	32 secs	36 secs



Gas Production with Gold is the Same

Gold and platinum produce the same volume of microbubbles in both normal and misuse conditions¹



- Misuse conditions include thermocouple misalignment and intermittent tissue contact
- Coagulum: non-adherent solid particles were not observed in any of the filters post ablation

1. Haines et al. Evaluation of gold/platinum electrode multipolar phased RF ablations in a swine model *In Vivo*: Microembolus production and energy delivery performance. ESC Poster 2012.

ContactIQ Sensitivity and Specificity Results

Sensitivity


- Correctly identified a lesion was present at >30s and >45s

Specificity

- Correctly identified a lesion was not present at <30s and <45s

Positive Predictive Value (PPV)

- Percent of time a lesion is predicted and one is present




Evaluation and Reduction of Asymptomatic Cerebral Embolism in Ablation of Atrial Fibrillation, but High Prevalence of Chronic Silent Infarction: Results of the ERACE Trial
Atul Verma, Philippe Debruyne, Stefano Nardi, Thomas Deneke, Yves DeGreef, Stefan Spitzer, Jörn O. Balzer and Lucas Boersma

Circ Arrhythm Electrophysiol. published online August 27, 2013;
Circulation: Arrhythmia and Electrophysiology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3149. Online ISSN: 1941-3084

Conclusions - Applying procedural changes to MER ablation significantly reduces the ACE incidence to 1.7%, which is on the low end of reported ACE rates of any technology.

PVAC GOLD ACE Rate is Consistent with Previously-Reported Microembolism Reductions




Caution: Clinical results across studies/protocols may not be comparable.

All studies included used 1.5T MRI scanner and used a consistent lesion definition as per Gaita/Herrera-Siklody (DWI + ADC + FLAIR)

PVAC GOLD May Be More Efficient than PVAC

Comparing data from PRECISION GOLD (PVAC GOLD) and ERACE (PVAC) shows more Effective Contact and less RF applications with PVAC GOLD

	PRECISION GOLD	ERACE
Procedure time	92 ± 25 min	100 ± 35 min
LA dwell time	59 ± 17 min	64 ± 27 min
Fluoroscopy time	16 ± 6 min	-
Effective contact	36s	32s



PVAC vs point by point PVI: follow up

Table 2 PVAC vs. point by point RF ablation in AF

	Technique	Patients (N)	Success %	FU duration
Paroxysmal atrial fibrillation (PAF)				
Bulava et al. ⁶	PVAC	51	76	200 ± 13 days
	Point by point	51	71	
Khaykin et al. ⁷	PVAC	31	67	6 months
	Point by point	19	54	
Beukema et al. ¹⁰	PVAC	89	82	367 ± 139 days
	Point by point	96	80	
Choo et al. ⁸	PVAC	30	73	6 months
	Point by point	43	49	
Tvig et al. ¹²	PVAC	27	74	> 12 months (+ or =?)
	Point by point	47	68	
Persistent atrial fibrillation (PERS) AF				
Choo et al. ⁸	PVAC	8	50	6 months
	Point by point	28	25	
Tvig et al. ¹²	PVAC/MAAC/MAASC	22	46	> 12 months (> or =?)
	Point by point + substrate	23	61	
PAF + PERS AF				
Bittner et al. ⁹	PVAC	40	72	254 ± 99 days
	Point by point	40	68	


FU, follow-up.

Conventional radiofrequency catheter ablation compared to multi-electrode ablation for atrial fibrillation


Pim Gal, Alissa E.S.M. Aarntzen, Jaap Jan J. Smit, Ahmet Adiyaman, Anand R. Ramdat Misier, Peter Paul H.M. Delnoy, Arif Elvan*

Department of Cardiology, Isala Klinieken, Zwolle, The Netherlands


Safety Profile



	Total group n = 460	cPVI n = 230	MER n = 230	P
Age (years)	56.3			
Gender men (%)	347			
BMI (kg/m ²)	27.6			
LA size in PSLAX (mm)	41.0			
CHA ₂ DS ₂ -VASc score				
0	178			
1	160			
2	75			
3	36			
4	2			
5-7	1			
Co-morbidity (%)				
Hypertension	161			
Diabetes mellitus	30			
Previous TIA/stroke	25			
Structural heart disease	53			
Type AF: paroxysmal	375			
Failed AADs (range)	1.58			
Class I	282 (61.3%)	139 (60.4%)	143 (62.4%)	0.5331
Class III	329 (71.5%)	161 (70.0%)	168 (73.4%)	0.7651
AF duration (years)	8.3 (±5.1)	8.6 (±5.2)	7.9 (±5.0)	0.154*




Procedure Time




5 year Follow-Up with PVAC vs. Irrigated RF

Very long-term follow-up shows improved efficiency, improved safety and similar effectiveness with first-generation PVAC vs. Irrigated RF


Single Procedure Success off Drugs



Safety Profile



Procedure Time



■ - PVAC ■ - Irrigated RF

Gal P, et al, Conventional radiofrequency catheter ablation compared to multi-electrode ablation for atrial fibrillation. *Int J Cardiol.* Published online August 2014.

Phased multipolar radiofrequency pulmonary vein isolation is as effective and safe as conventional irrigated point-to-point ablation. A prospective randomised 1-year implantable cardiac monitoring device follow-up trial

Received: 11 April 2015 / Accepted: 29 July 2015
© Springer Science+Business Media New York 2015

S. J. Podd¹ · A. N. Sulke¹ · C. Sugihara¹ · S. S. Furniss¹





Fig. 1 AF burden pre-ablation, at 3, 6, 9, and 12 months for the PMRA and Conv groups

Procedural times were significantly shorter for the PMRA group (PMRA 79±19 min vs Conv 139±28 min, $p<0.001$).



Long-term Follow-Up of Ablation with Multiple Generations of Duty-Cycled Phased Radiofrequency Ablation Using a Subcutaneous Monitoring Device.

Giovanni Rovaris¹, et al.
 1 San Gerardo Hospital, Monza, Italy




Introduction

Multi-electrode radiofrequency (RF) ablation using phased, duty-cycled energy (PVAC, Medtronic, Minneapolis, USA) is a promising technique to treat atrial fibrillation that has reported equivalent freedom from AF as conventional point by point RF, with significantly reduced procedure times. Second-generation PVAC GOLD technology has recently been introduced, incorporating gold electrodes with potentially improved energy efficiency. At this point, few data are available on the acute procedural efficiency or the long-term freedom from AF with this novel device. Additionally, few data are available on freedom from AF when assessed with an implantable loop recorder, as opposed to a traditional Holter monitor. These highly sensitive devices may offer improved detection of AF at follow-up.

Methods

104 AF patients were ablated with PVAC and PVAC GOLD at our center between December 2010 and October 2014. 27% (28/104) were persistent. 71 subjects were ablated with the first-generation PVAC catheter and older versions of the GENius generator, 18 subjects were ablated with PVAC and the new GENius v15.1 generator and 15 subjects were ablated with the novel PVAC GOLD catheter and the new GENius 15.1 generator. 77% (80/104) subjects were followed with an implantable subcutaneous monitoring device to assess freedom from AF (Reveal, Medtronic, Minneapolis, USA)



77% followed with ILR

Results


Baseline characteristics

	Overall	PVAC	PVAC GOLD
Age (years), mean±std	58±12	59±12	57±11
Gender (male), %	68%	66%	76%
Left Atrial Diameter (mm), mean±std	40,6±4,3	40,4±4,7	41,5±2,7


2.9% adverse events occurred (3 vascular access complications).



Average procedure time was 111 ± 29 min. 115 min with PVAC and 88min with PVAC GOLD; p=0.0004.



Average number of RF applications was 19 ± 6. 19.8 with PVAC and 14.5 with PVAC GOLD; p=0.0005.



At an average follow-up of 27 ± 14 months, 74% (77/104) of patients were in sinus rhythm. At an average follow-up of 5 ± 2 months, 93% (14/15) of patients treated with the novel PVAC GOLD catheter were free from AF.

Conclusions


These data demonstrate strong clinical effectiveness of Phased RF technology at long-term follow-up using a highly sensitive implantable monitor. Furthermore, they suggest improved efficiency of the second-generation PVAC GOLD device versus the predicate PVAC catheter.

Long-term Follow-Up of Ablation with Multiple Generations of Duty-Cycled Phased Radiofrequency Ablation Using a Subcutaneous Monitoring Device.

Giovanni Rovaris¹, Elena Piazzini¹, Sergio De Ceglia¹ et al.

¹ San Gerardo Hospital, Monza, Italy

104 AF patients were ablated with PVAC and PVAC GOLD at our center between December 2010 and October 2014. 27% (28/104) were persistent. 71 subjects were ablated with the first-generation PVAC catheter and older versions of the GENius generator, 18 subjects were ablated with PVAC and the new GENius v15.1 generator and 15 subjects were ablated with the novel PVAC GOLD catheter and the new GENius 15.1 generator. 77% (80/104) subjects were followed with an implantable subcutaneous monitoring device to assess freedom from AF (Reveal, Medtronic, Minneapolis, USA)




	Overall	PVAC	PVAC GOLD
Age (years), mean \pmstd	58 \pm 12	59 \pm 12	57 \pm 11
Gender (male), %	68%	66%	76%
Left Atrial Diameter (mm), mean \pmstd	40,6 \pm 4,3	40,4 \pm 4,7	41,5 \pm 2,7


Long-term Follow-Up of Ablation with Multiple Generations of Duty-Cycled Phased Radiofrequency Ablation Using a Subcutaneous Monitoring Device.

Giovanni Rovaris¹, Elena Piazzini¹, Sergio De Ceglia¹ et al.
¹ San Gerardo Hospital, Monza, Italy

- Average procedure time was 111 ± 29 min. 115 min with PVAC and 88min with PVAC GOLD; $p=0.0004$.




- Average number of RF applications was 19 ± 6 . 19.8 with PVAC and 14.5 with PVAC GOLD; $p=0.0005$.



Long-term Follow-Up of Ablation with Multiple Generations of Duty-Cycled Phased Radiofrequency Ablation Using a Subcutaneous Monitoring Device.

Giovanni Rovaris¹, Elena Piazzzi¹, Sergio De Ceglia¹ et al.
1 San Gerardo Hospital, Monza, Italy

2.9% adverse events occurred
(3 vascular access complications)



RESULTS

- At an average follow-up of 27 ± 14 months, 74% (77/104) of patients were in sinus rhythm.
- At an average follow-up of 5 ± 2 months, 93% (14/15) of patients treated with the novel PVAC GOLD catheter were free from AF.

NEW STUDIES ONGOING

PVAC GOLD Versus Irrigated RF Single Tip Catheter With Contact FORCE Ablation of the Pulmonary Veins for Treatment of Drug Refractory Symptomatic Paroxysmal and Persistent Atrial Fibrillation (GOLD-FORCE)

GOLD AF Registry to Capture Real-World Insights Using Medtronic Phased RF Ablation to Treat Patients with Atrial Fibrillation

Conclusions

Phased RF technology demonstrate strong clinical effectiveness at long term follow up using a highly sensitive implantable monitor.

The novel catheter design of PVAC GOLD arrey and the Genius Contact IQ may improve :

- safety, reducing embolic events
- better tissue contact, with 20° forward tilt and the real contact with contact force
- reducing procedural time
- reducing application of energy